Abstract
This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R.sup.1 and R.sup.9 is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).
Original language | English |
---|---|
Patent number | US7,888,350 |
Publication status | Published - 15 Feb 2011 |
Fingerprint
Dive into the research topics of '3,7-diamino-10H-phenothiazine salts and their use: WO2007110627'. Together they form a unique fingerprint.Impacts
-
Development of treatments & diagnostics for Alzheimer’s disease
John Storey (Coordinator)
Impact: Other Impacts
-
Discovery and commercialisation of an entirely new drug for the treatment of Alzheimer's disease
Claude Wischik (Participant), Charles Harrington (Participant), John Storey (Participant), Janet Rickard (Participant), David Horsley (Participant), Thomas Baddeley (Participant), Steven Kemp (Participant), James Sinclair (Participant), Claudia Zabke (Participant), F. Theuring (Participant), F Stamer (Participant) & C Marshall (Participant)
Impact: Quality of life Impacts, Economic Impacts